Pages

Saturday, October 30, 2010

original article

 
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Anaplastic Lymphoma Kinase Inhibition in Non Small-Cell Lung Cancer
October 28, 2010 | E.L. Kwak and Others
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally bioavailable ALK inhibitor, produced a 57% response rate in this subgroup, with mild grade 1 or 2 toxic effects.
editorial
Crizotinib — Latest Champion in the Cancer Wars?
October 28, 2010 | B. Hallberg and R.H. Palmer
SpecialtiesHematology/Oncology
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
original article
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
October 28, 2010 | G. Paré and Others
Published Online August 29, 2010
Clopidogrel must be metabolized to an active form to be effective. Cytochrome P-450 variants resulting in slow metabolism may reduce clinical efficacy. This study in patients with acute coronary syndromes or atrial fibrillation did not confirm diminished efficacy in those with slow metabolism.
  • CME
Thumbnail Graphic - Health Policy and Reform Center
Perspective Online First
Health Care in the 2010 Congressional Election
October 27, 2010 | R.J. Blendon and J.M. Benson
DOI: 10.1056/NEJMp1011714
Writing New Rules for Insurers — Progress on the Medical Loss Ratio
October 27, 2010 | T.S. Jost
DOI: 10.1056/NEJMp1011717
A “Broader Regulatory Scheme” — The Constitutionality of Health Care Reform
October 27, 2010 | S. Rosenbaum
DOI: 10.1056/NEJMp1010850

Featured Multimedia

Current Issue: October 28, 2010

Weekly Audio Summary
Browse Past Issues
original articles
Anaplastic Lymphoma Kinase Inhibition in
Non–Small-Cell Lung Cancer
E.L. Kwak and Others
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
G. Paré and Others
Published Online August 29, 2010
  • CME
Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma
S.P. Peters and Others
Published Online September 19, 2010
Brief Report: Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
J.E. Butrynski and Others
Brief Report: EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Y.L. Choi and Others
clinical practice
Recurrent Miscarriage
D.W. Branch, M. Gibson, and R.M. Silver
  • CME
  • Full Text Audio
images in clinical medicine
A Foreign Body
R. Flores-Suarez and J. Reyes-del Valle
  • Free Full Text
Air in the Middle of the Abdomen
F. Catena and S. Di Saverio
  • Free Full Text
case records of the massachusetts
general hospital
A Woman with Blurred Vision and
Renal Failure
L.H. Young and Others
  • CME
editorials
Crizotinib — Latest Champion in the
Cancer Wars?
B. Hallberg and R.H. Palmer
Products at Risk
G.D. Curfman, S. Morrissey, and J.M. Drazen
Published Online September 19, 2010
  • Free Full Text
Anticholinergics for Patients with Asthma?
L.J. Smith
Published Online September 19, 2010

Perspective

The Midterm Elections — High Stakes for
Health Policy
H.J. Aaron
Published Online October 6, 2010
  • Free Full Text
Resurrection of a Stem-Cell Funding Barrier — Dickey–Wicker in Court
G.J. Annas
Published Online September 15, 2010
  • Free Full Text
Thumbnail Graphic -- Why Health Care Is Going Home
Why Health Care Is Going Home
S.H. Landers
Published Online October 20, 2010
Correspondence

Online First

Perspective
Health Care in the 2010 Congressional Election
October 27, 2010 | R.J. Blendon and J.M. Benson DOI: 10.1056/NEJMp1011714
Perspective
Writing New Rules for Insurers — Progress on the Medical Loss Ratio
October 27, 2010 | T.S. Jost DOI: 10.1056/NEJMp1011717
Perspective
A “Broader Regulatory Scheme” — The Constitutionality of Health Care Reform
October 27, 2010 | S. Rosenbaum DOI: 10.1056/NEJMp1010850
Original Article
Teriparatide and Osseous Regeneration in the Oral Cavity
October 16, 2010 | J.D. Bashutski and Others | DOI: 10.1056/NEJMoa1005361
at 1:54 AM

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)